Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur l'Université de Trèves

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Identifieur interne : 000674 ( PascalFrancis/Corpus ); précédent : 000673; suivant : 000675

Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy

Auteurs : P. Hadji ; M. Ziller ; D. G. Kieback ; W. Dornoff ; H. W. Tessen ; T. Menschik ; J. Kuck ; F. Melchert ; A. Hasenburg

Source :

RBID : Pascal:09-0309205

Descripteurs français

English descriptors

Abstract

Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0923-7534
A03   1    @0 Ann. oncol.
A05       @2 20
A06       @2 7
A08 01  1  ENG  @1 Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
A11 01  1    @1 HADJI (P.)
A11 02  1    @1 ZILLER (M.)
A11 03  1    @1 KIEBACK (D. G.)
A11 04  1    @1 DORNOFF (W.)
A11 05  1    @1 TESSEN (H. W.)
A11 06  1    @1 MENSCHIK (T.)
A11 07  1    @1 KUCK (J.)
A11 08  1    @1 MELCHERT (F.)
A11 09  1    @1 HASENBURG (A.)
A14 01      @1 Department of Gynecology, University Hospital of Giessen and Marburg @2 Marburg @3 DEU @Z 1 aut. @Z 2 aut.
A14 02      @1 Helios Kliniken @2 Aue @3 DEU @Z 3 aut.
A14 03      @1 Klinikum Mutterhaus der Borromaerinnen @2 Trier @3 DEU @Z 4 aut.
A14 04      @1 Onkologische Schwerpunktpraxis @2 Goslar @3 DEU @Z 5 aut.
A14 05      @1 Pfizer, Specialty Brand Team Europe @2 Paris @3 FRA @Z 6 aut.
A14 06      @1 Independent Clinical Research Consulting, Bölschestrasse @2 Berlin @3 DEU @Z 7 aut.
A14 07      @1 University of Mannheim @2 Mannheim @3 DEU @Z 8 aut.
A14 08      @1 Freiburg University, Frauenklinik @2 Freiburg @3 DEU @Z 9 aut.
A20       @1 1203-1209
A21       @1 2009
A23 01      @0 ENG
A43 01      @1 INIST @2 22429 @5 354000187188000090
A44       @0 0000 @1 © 2009 INIST-CNRS. All rights reserved.
A45       @0 30 ref.
A47 01  1    @0 09-0309205
A60       @1 P
A61       @0 A
A64 01  1    @0 Annals of oncology
A66 01      @0 GBR
C01 01    ENG  @0 Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.
C02 01  X    @0 002B02R
C02 02  X    @0 002B20E02
C02 03  X    @0 002B15A
C03 01  X  FRE  @0 Exémestane @2 NK @2 FR @5 01
C03 01  X  ENG  @0 Exemestane @2 NK @2 FR @5 01
C03 01  X  SPA  @0 Exemestano @2 NK @2 FR @5 01
C03 02  X  FRE  @0 Tamoxifène @2 NK @2 FR @5 02
C03 02  X  ENG  @0 Tamoxifene @2 NK @2 FR @5 02
C03 02  X  SPA  @0 Tamoxifeno @2 NK @2 FR @5 02
C03 03  X  FRE  @0 Os @5 03
C03 03  X  ENG  @0 Bone @5 03
C03 03  X  SPA  @0 Hueso @5 03
C03 04  X  FRE  @0 Santé @5 04
C03 04  X  ENG  @0 Health @5 04
C03 04  X  SPA  @0 Salud @5 04
C03 05  X  FRE  @0 Essai clinique @5 05
C03 05  X  ENG  @0 Clinical trial @5 05
C03 05  X  SPA  @0 Ensayo clínico @5 05
C03 06  X  FRE  @0 Allemagne @2 NG @5 06
C03 06  X  ENG  @0 Germany @2 NG @5 06
C03 06  X  SPA  @0 Alemania @2 NG @5 06
C03 07  X  FRE  @0 Prospective @5 07
C03 07  X  ENG  @0 Prospective @5 07
C03 07  X  SPA  @0 Prospectiva @5 07
C03 08  X  FRE  @0 Randomisation @5 08
C03 08  X  ENG  @0 Randomization @5 08
C03 08  X  SPA  @0 Aleatorización @5 08
C03 09  X  FRE  @0 Inhibiteur de l'aromatase @5 09
C03 09  X  ENG  @0 Aromatase inhibitor @5 09
C03 09  X  SPA  @0 Inhibidor aromatase @5 09
C03 10  X  FRE  @0 Densité minérale osseuse @5 10
C03 10  X  ENG  @0 Bone mineral density @5 10
C03 10  X  SPA  @0 Masa mineral ósea @5 10
C03 11  X  FRE  @0 Précoce @5 11
C03 11  X  ENG  @0 Early @5 11
C03 11  X  SPA  @0 Precoz @5 11
C03 12  X  FRE  @0 Cancer du sein @2 NM @5 12
C03 12  X  ENG  @0 Breast cancer @2 NM @5 12
C03 12  X  SPA  @0 Cáncer del pecho @2 NM @5 12
C03 13  X  FRE  @0 Fracture @5 13
C03 13  X  ENG  @0 Fracture @5 13
C03 13  X  SPA  @0 Fractura @5 13
C03 14  X  FRE  @0 Ostéoporose @5 14
C03 14  X  ENG  @0 Osteoporosis @5 14
C03 14  X  SPA  @0 Osteoporosis @5 14
C03 15  X  FRE  @0 Anticancéreux @5 23
C03 15  X  ENG  @0 Antineoplastic agent @5 23
C03 15  X  SPA  @0 Anticanceroso @5 23
C07 01  X  FRE  @0 Europe @2 NG
C07 01  X  ENG  @0 Europe @2 NG
C07 01  X  SPA  @0 Europa @2 NG
C07 02  X  FRE  @0 Dérivé de l'androstane @2 FR @5 37
C07 02  X  ENG  @0 Androstane derivatives @2 FR @5 37
C07 02  X  SPA  @0 Androstano derivado @2 FR @5 37
C07 03  X  FRE  @0 Estrogen synthase @2 FE @5 38
C07 03  X  ENG  @0 Estrogen synthase @2 FE @5 38
C07 03  X  SPA  @0 Estrogen synthase @2 FE @5 38
C07 04  X  FRE  @0 Enzyme @2 FE
C07 04  X  ENG  @0 Enzyme @2 FE
C07 04  X  SPA  @0 Enzima @2 FE
C07 05  X  FRE  @0 Inhibiteur enzyme @5 39
C07 05  X  ENG  @0 Enzyme inhibitor @5 39
C07 05  X  SPA  @0 Inhibidor enzima @5 39
C07 06  X  FRE  @0 Stéroïde @5 40
C07 06  X  ENG  @0 Steroid @5 40
C07 06  X  SPA  @0 Esteroide @5 40
C07 07  X  FRE  @0 Antihormone @5 41
C07 07  X  ENG  @0 Antihormone @5 41
C07 07  X  SPA  @0 Antihormona @5 41
C07 08  X  FRE  @0 Antioestrogène @5 42
C07 08  X  ENG  @0 Antiestrogen @5 42
C07 08  X  SPA  @0 Antiestrógeno @5 42
C07 09  X  FRE  @0 Composé non stéroïde @5 43
C07 09  X  ENG  @0 Non steroid compound @5 43
C07 09  X  SPA  @0 Compuesto no esteroide @5 43
C07 10  X  FRE  @0 Modulateur sélectif des récepteurs aux oestrogènes @5 44
C07 10  X  ENG  @0 Selective estrogen receptor modulator @5 44
C07 10  X  SPA  @0 Modulador selectivo del receptor de estrógeno @5 44
C07 11  X  FRE  @0 Système ostéoarticulaire @5 45
C07 11  X  ENG  @0 Osteoarticular system @5 45
C07 11  X  SPA  @0 Sistema osteoarticular @5 45
C07 12  X  FRE  @0 Tumeur maligne @2 NM @5 46
C07 12  X  ENG  @0 Malignant tumor @2 NM @5 46
C07 12  X  SPA  @0 Tumor maligno @2 NM @5 46
C07 13  X  FRE  @0 Cancer @2 NM
C07 13  X  ENG  @0 Cancer @2 NM
C07 13  X  SPA  @0 Cáncer @2 NM
C07 14  X  FRE  @0 Pathologie de la glande mammaire @2 NM @5 47
C07 14  X  ENG  @0 Mammary gland diseases @2 NM @5 47
C07 14  X  SPA  @0 Glándula mamaria patología @2 NM @5 47
C07 15  X  FRE  @0 Pathologie du sein @2 NM @5 48
C07 15  X  ENG  @0 Breast disease @2 NM @5 48
C07 15  X  SPA  @0 Seno patología @2 NM @5 48
C07 16  X  FRE  @0 Pathologie du système ostéoarticulaire @5 49
C07 16  X  ENG  @0 Diseases of the osteoarticular system @5 49
C07 16  X  SPA  @0 Sistema osteoarticular patología @5 49
C07 17  X  FRE  @0 Traumatisme @5 50
C07 17  X  ENG  @0 Trauma @5 50
C07 17  X  SPA  @0 Traumatismo @5 50
N21       @1 222
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 09-0309205 INIST
ET : Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
AU : HADJI (P.); ZILLER (M.); KIEBACK (D. G.); DORNOFF (W.); TESSEN (H. W.); MENSCHIK (T.); KUCK (J.); MELCHERT (F.); HASENBURG (A.)
AF : Department of Gynecology, University Hospital of Giessen and Marburg/Marburg/Allemagne (1 aut., 2 aut.); Helios Kliniken/Aue/Allemagne (3 aut.); Klinikum Mutterhaus der Borromaerinnen/Trier/Allemagne (4 aut.); Onkologische Schwerpunktpraxis/Goslar/Allemagne (5 aut.); Pfizer, Specialty Brand Team Europe/Paris/France (6 aut.); Independent Clinical Research Consulting, Bölschestrasse/Berlin/Allemagne (7 aut.); University of Mannheim/Mannheim/Allemagne (8 aut.); Freiburg University, Frauenklinik/Freiburg/Allemagne (9 aut.)
DT : Publication en série; Niveau analytique
SO : Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2009; Vol. 20; No. 7; Pp. 1203-1209; Bibl. 30 ref.
LA : Anglais
EA : Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.
CC : 002B02R; 002B20E02; 002B15A
FD : Exémestane; Tamoxifène; Os; Santé; Essai clinique; Allemagne; Prospective; Randomisation; Inhibiteur de l'aromatase; Densité minérale osseuse; Précoce; Cancer du sein; Fracture; Ostéoporose; Anticancéreux
FG : Europe; Dérivé de l'androstane; Estrogen synthase; Enzyme; Inhibiteur enzyme; Stéroïde; Antihormone; Antioestrogène; Composé non stéroïde; Modulateur sélectif des récepteurs aux oestrogènes; Système ostéoarticulaire; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie du système ostéoarticulaire; Traumatisme
ED : Exemestane; Tamoxifene; Bone; Health; Clinical trial; Germany; Prospective; Randomization; Aromatase inhibitor; Bone mineral density; Early; Breast cancer; Fracture; Osteoporosis; Antineoplastic agent
EG : Europe; Androstane derivatives; Estrogen synthase; Enzyme; Enzyme inhibitor; Steroid; Antihormone; Antiestrogen; Non steroid compound; Selective estrogen receptor modulator; Osteoarticular system; Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Diseases of the osteoarticular system; Trauma
SD : Exemestano; Tamoxifeno; Hueso; Salud; Ensayo clínico; Alemania; Prospectiva; Aleatorización; Inhibidor aromatase; Masa mineral ósea; Precoz; Cáncer del pecho; Fractura; Osteoporosis; Anticanceroso
LO : INIST-22429.354000187188000090
ID : 09-0309205

Links to Exploration step

Pascal:09-0309205

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title>
<author>
<name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Helios Kliniken</s1>
<s2>Aue</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Klinikum Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Onkologische Schwerpunktpraxis</s1>
<s2>Goslar</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Pfizer, Specialty Brand Team Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Independent Clinical Research Consulting, Bölschestrasse</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name>
<affiliation>
<inist:fA14 i1="07">
<s1>University of Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name>
<affiliation>
<inist:fA14 i1="08">
<s1>Freiburg University, Frauenklinik</s1>
<s2>Freiburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">09-0309205</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0309205 INIST</idno>
<idno type="RBID">Pascal:09-0309205</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000674</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</title>
<author>
<name sortKey="Hadji, P" sort="Hadji, P" uniqKey="Hadji P" first="P." last="Hadji">P. Hadji</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Ziller, M" sort="Ziller, M" uniqKey="Ziller M" first="M." last="Ziller">M. Ziller</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Kieback, D G" sort="Kieback, D G" uniqKey="Kieback D" first="D. G." last="Kieback">D. G. Kieback</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Helios Kliniken</s1>
<s2>Aue</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Dornoff, W" sort="Dornoff, W" uniqKey="Dornoff W" first="W." last="Dornoff">W. Dornoff</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Klinikum Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Tessen, H W" sort="Tessen, H W" uniqKey="Tessen H" first="H. W." last="Tessen">H. W. Tessen</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Onkologische Schwerpunktpraxis</s1>
<s2>Goslar</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Menschik, T" sort="Menschik, T" uniqKey="Menschik T" first="T." last="Menschik">T. Menschik</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Pfizer, Specialty Brand Team Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Kuck, J" sort="Kuck, J" uniqKey="Kuck J" first="J." last="Kuck">J. Kuck</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Independent Clinical Research Consulting, Bölschestrasse</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Melchert, F" sort="Melchert, F" uniqKey="Melchert F" first="F." last="Melchert">F. Melchert</name>
<affiliation>
<inist:fA14 i1="07">
<s1>University of Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Hasenburg, A" sort="Hasenburg, A" uniqKey="Hasenburg A" first="A." last="Hasenburg">A. Hasenburg</name>
<affiliation>
<inist:fA14 i1="08">
<s1>Freiburg University, Frauenklinik</s1>
<s2>Freiburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint>
<date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antineoplastic agent</term>
<term>Aromatase inhibitor</term>
<term>Bone</term>
<term>Bone mineral density</term>
<term>Breast cancer</term>
<term>Clinical trial</term>
<term>Early</term>
<term>Exemestane</term>
<term>Fracture</term>
<term>Germany</term>
<term>Health</term>
<term>Osteoporosis</term>
<term>Prospective</term>
<term>Randomization</term>
<term>Tamoxifene</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Exémestane</term>
<term>Tamoxifène</term>
<term>Os</term>
<term>Santé</term>
<term>Essai clinique</term>
<term>Allemagne</term>
<term>Prospective</term>
<term>Randomisation</term>
<term>Inhibiteur de l'aromatase</term>
<term>Densité minérale osseuse</term>
<term>Précoce</term>
<term>Cancer du sein</term>
<term>Fracture</term>
<term>Ostéoporose</term>
<term>Anticancéreux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0923-7534</s0>
</fA01>
<fA03 i2="1">
<s0>Ann. oncol.</s0>
</fA03>
<fA05>
<s2>20</s2>
</fA05>
<fA06>
<s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>HADJI (P.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>ZILLER (M.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>KIEBACK (D. G.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>DORNOFF (W.)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>TESSEN (H. W.)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>MENSCHIK (T.)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>KUCK (J.)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>MELCHERT (F.)</s1>
</fA11>
<fA11 i1="09" i2="1">
<s1>HASENBURG (A.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Gynecology, University Hospital of Giessen and Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Helios Kliniken</s1>
<s2>Aue</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Klinikum Mutterhaus der Borromaerinnen</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Onkologische Schwerpunktpraxis</s1>
<s2>Goslar</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05">
<s1>Pfizer, Specialty Brand Team Europe</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06">
<s1>Independent Clinical Research Consulting, Bölschestrasse</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07">
<s1>University of Mannheim</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08">
<s1>Freiburg University, Frauenklinik</s1>
<s2>Freiburg</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20>
<s1>1203-1209</s1>
</fA20>
<fA21>
<s1>2009</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>22429</s2>
<s5>354000187188000090</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>09-0309205</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Annals of oncology</s0>
</fA64>
<fA66 i1="01">
<s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02R</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B20E02</s0>
</fC02>
<fC02 i1="03" i2="X">
<s0>002B15A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Exémestane</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Exemestane</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Exemestano</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Tamoxifène</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Tamoxifene</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Tamoxifeno</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Os</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Bone</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Hueso</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Santé</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Health</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Salud</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Essai clinique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Clinical trial</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Ensayo clínico</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Allemagne</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Germany</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Alemania</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Prospective</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Prospective</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Prospectiva</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Randomisation</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Randomization</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Aleatorización</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Inhibiteur de l'aromatase</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Aromatase inhibitor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Inhibidor aromatase</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Densité minérale osseuse</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Bone mineral density</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Masa mineral ósea</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Précoce</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Early</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Precoz</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Breast cancer</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Fracture</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Fracture</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Fractura</s0>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Ostéoporose</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Osteoporosis</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Osteoporosis</s0>
<s5>14</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Anticancéreux</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG">
<s0>Antineoplastic agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA">
<s0>Anticanceroso</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Europe</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Europa</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Dérivé de l'androstane</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Androstane derivatives</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Androstano derivado</s0>
<s2>FR</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Estrogen synthase</s0>
<s2>FE</s2>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Inhibiteur enzyme</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Enzyme inhibitor</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Inhibidor enzima</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Stéroïde</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Steroid</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Esteroide</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Antihormone</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Antihormone</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Antihormona</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Antioestrogène</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Antiestrogen</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Antiestrógeno</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Composé non stéroïde</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Non steroid compound</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Compuesto no esteroide</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Modulateur sélectif des récepteurs aux oestrogènes</s0>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Selective estrogen receptor modulator</s0>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Modulador selectivo del receptor de estrógeno</s0>
<s5>44</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Système ostéoarticulaire</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Osteoarticular system</s0>
<s5>45</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Sistema osteoarticular</s0>
<s5>45</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE">
<s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG">
<s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA">
<s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="13" i2="X" l="FRE">
<s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="13" i2="X" l="ENG">
<s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="13" i2="X" l="SPA">
<s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="14" i2="X" l="FRE">
<s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>47</s5>
</fC07>
<fC07 i1="14" i2="X" l="ENG">
<s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>47</s5>
</fC07>
<fC07 i1="14" i2="X" l="SPA">
<s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>47</s5>
</fC07>
<fC07 i1="15" i2="X" l="FRE">
<s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>48</s5>
</fC07>
<fC07 i1="15" i2="X" l="ENG">
<s0>Breast disease</s0>
<s2>NM</s2>
<s5>48</s5>
</fC07>
<fC07 i1="15" i2="X" l="SPA">
<s0>Seno patología</s0>
<s2>NM</s2>
<s5>48</s5>
</fC07>
<fC07 i1="16" i2="X" l="FRE">
<s0>Pathologie du système ostéoarticulaire</s0>
<s5>49</s5>
</fC07>
<fC07 i1="16" i2="X" l="ENG">
<s0>Diseases of the osteoarticular system</s0>
<s5>49</s5>
</fC07>
<fC07 i1="16" i2="X" l="SPA">
<s0>Sistema osteoarticular patología</s0>
<s5>49</s5>
</fC07>
<fC07 i1="17" i2="X" l="FRE">
<s0>Traumatisme</s0>
<s5>50</s5>
</fC07>
<fC07 i1="17" i2="X" l="ENG">
<s0>Trauma</s0>
<s5>50</s5>
</fC07>
<fC07 i1="17" i2="X" l="SPA">
<s0>Traumatismo</s0>
<s5>50</s5>
</fC07>
<fN21>
<s1>222</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 09-0309205 INIST</NO>
<ET>Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy</ET>
<AU>HADJI (P.); ZILLER (M.); KIEBACK (D. G.); DORNOFF (W.); TESSEN (H. W.); MENSCHIK (T.); KUCK (J.); MELCHERT (F.); HASENBURG (A.)</AU>
<AF>Department of Gynecology, University Hospital of Giessen and Marburg/Marburg/Allemagne (1 aut., 2 aut.); Helios Kliniken/Aue/Allemagne (3 aut.); Klinikum Mutterhaus der Borromaerinnen/Trier/Allemagne (4 aut.); Onkologische Schwerpunktpraxis/Goslar/Allemagne (5 aut.); Pfizer, Specialty Brand Team Europe/Paris/France (6 aut.); Independent Clinical Research Consulting, Bölschestrasse/Berlin/Allemagne (7 aut.); University of Mannheim/Mannheim/Allemagne (8 aut.); Freiburg University, Frauenklinik/Freiburg/Allemagne (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Annals of oncology; ISSN 0923-7534; Royaume-Uni; Da. 2009; Vol. 20; No. 7; Pp. 1203-1209; Bibl. 30 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss. Patients and methods: Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment. Results: One hundred and sixty-one patients were assessable. Tamoxifen treatment resulted in a 0.5% increase from baseline in BMD at the spine, which was maintained at 12 months. Exemestane-treated patients experienced a 2.6% decrease from baseline in BMD at the spine at 6 months and a further 0.2% decrease at 12 months. There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months (P = 0.0026 and P = 0.0008, respectively). The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months (P = 0.0009 and P = 0.04, respectively). There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck. Conclusions: Exemestane treatment resulted in an increase in bone loss at 6 months; bone loss stabilised after 6- to 12-month treatment.</EA>
<CC>002B02R; 002B20E02; 002B15A</CC>
<FD>Exémestane; Tamoxifène; Os; Santé; Essai clinique; Allemagne; Prospective; Randomisation; Inhibiteur de l'aromatase; Densité minérale osseuse; Précoce; Cancer du sein; Fracture; Ostéoporose; Anticancéreux</FD>
<FG>Europe; Dérivé de l'androstane; Estrogen synthase; Enzyme; Inhibiteur enzyme; Stéroïde; Antihormone; Antioestrogène; Composé non stéroïde; Modulateur sélectif des récepteurs aux oestrogènes; Système ostéoarticulaire; Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie du système ostéoarticulaire; Traumatisme</FG>
<ED>Exemestane; Tamoxifene; Bone; Health; Clinical trial; Germany; Prospective; Randomization; Aromatase inhibitor; Bone mineral density; Early; Breast cancer; Fracture; Osteoporosis; Antineoplastic agent</ED>
<EG>Europe; Androstane derivatives; Estrogen synthase; Enzyme; Enzyme inhibitor; Steroid; Antihormone; Antiestrogen; Non steroid compound; Selective estrogen receptor modulator; Osteoarticular system; Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Diseases of the osteoarticular system; Trauma</EG>
<SD>Exemestano; Tamoxifeno; Hueso; Salud; Ensayo clínico; Alemania; Prospectiva; Aleatorización; Inhibidor aromatase; Masa mineral ósea; Precoz; Cáncer del pecho; Fractura; Osteoporosis; Anticanceroso</SD>
<LO>INIST-22429.354000187188000090</LO>
<ID>09-0309205</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000674 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000674 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Rhénanie
   |area=    UnivTrevesV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0309205
   |texte=   Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
}}
Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Jul 22 16:29:01 2017. Site generation: Wed Feb 28 14:55:37 2024